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Abstract Mouse prostaglandin EP3 receptor consists of three
isoforms, EP3K, L and Q, with different carboxy-terminal tails.
To assess the role of their carboxy-terminal tails in membrane
targeting, we examined subcellular localization of myc-tagged
EP3 isoforms expressed in MDCK cells. Two isoforms, EP3K
and EP3L, were localized in the intracellular compartment but
not in the plasma membrane, while the EP3Q isoform was found
in the lateral plasma membrane and in part in the intracellular
compartment. Mutant EP3 receptor lacking the carboxy-
terminal tail was localized in the intracellular compartment but
not in the plasma membrane. Thus, EP3 isoforms differ in
subcellular targeting, and the carboxy-terminal tails play an
important role in determination of the membrane targeting of
EP3 receptor.
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1. Introduction
Prostaglandin (PG) E2 exhibits a broad range of biological
actions in diverse tissues through its binding to speci¢c recep-
tors on plasma membrane [1]. PGE receptors are pharmaco-
logically subdivided into four subtypes, EP1, EP2, EP3, and
EP4, on the basis of their responses to various agonists and
antagonists [2,3]. Among the four subtypes, the EP3 subtype
has been most well characterized and involved in diverse
PGE2 actions [3]. We have cloned the mouse EP3 receptor
and demonstrated that this receptor is a G protein-coupled
receptor (GPCR) that engages in inhibition of adenylate cy-
clase [4]. Furthermore, we have identi¢ed the three isoforms
of the mouse EP3 receptor with di¡erent carboxy-terminal
tail, EP3K, EP3L and EP3Q, which are produced through al-
ternative splicing [5,6]. Our previous studies revealed that
these isoforms di¡ered in agonist dependent desensitization
[7] and in agonist-independent constitutive Gi activity [8,9].
One of the prominent EP3 actions is inhibition of sodium
and water reabsorption in collecting tubules of kidney [10],
and this action is mediated by Gi [11]. Like all other epithelial
cells, renal tubule cells are highly polarized, and their plasma
membranes are divided into two separate membrane domains,
apical and basolateral [12]. Many membrane proteins tend to
be localized in either the apical or the basolateral membrane,
and the polarized distribution is thought to be important for
the function of these proteins. Although either luminal or
basolateral PGE2 has been reported to exhibit Gi activity in
canine cortical collecting tubule cells [13], membrane polar-
ization of EP3 receptors has not yet been elucidated. We here
investigated subcellular targeting of three EP3 isoforms in
Madin^Darby canine kidney (MDCK) cells, which are gener-
ally used as a model of polarized epithelial cells, and demon-
strated that these isoforms di¡ered in subcellular targeting,
that is, EP3K and EP3L isoforms were localized in the intra-
cellular compartment, while EP3Q isoform was targeted to the
lateral plasma membrane.
2. Materials and methods
2.1. Materials
MDCK cell line, sulprostone and anti-telencephalin (tln) antibody
were generous gifts from Drs. K.E. Mostov (University of California,
San Francisco, CA, USA), K.-H. Thierauch (Schering, Germany) and
Y. Yoshihara (RIKEN Brain Science Institute, Saitama, Japan), re-
spectively. cDNA for rabbit tln was also kindly provided by Dr. Y.
Yoshihara. Alexa1488-phalloidin was purchased from Molecular
Probes; rhodamine-conjugated goat F(abP)2 anti-rabbit IgG (H and
L) and rhodamine-conjugated goat F(abP)2 anti-mouse IgG (H and L)
were from Leinco Technologies.
2.2. DNA construction
Mutant EP3 receptor T-335, which lacked the C-terminal domain
from the alternative splicing site, was generated as described previ-
ously [14]. For construction of myc-tagged receptors, cDNAs of three
EP3 isoforms and T-335 receptor were cloned in frame into a
pcDNA3 eukaryotic expression vector (Invitrogen) containing the
myc-epitope tag sequence at the 5P end. C-terminal-truncation mutant
tln (tln-S), lacking the last 56 amino acid residues, was generated by
PCR-mediated mutagenesis, and subcloned into a pcDNA3 vector.
For chimeric mutants of tln with the last 30 amino acid residues of
the mouse EP3K (tln-K) or the last 29 amino acid residues of the
mouse EP3Q (tln-Q) instead of the C-terminal domain of tln, a KpnI
site was created after the last amino acid of tln-S by PCR-mediated
mutagenesis, and this construct was subcloned into the pBluescript
SK(+) (tln-K/pBs). KpnI/EcoRI or KpnI/XbaI fragment encoding the
C-terminal domain of mouse EP3K or EP3Q isoform was generated by
PCR-mediated mutagenesis and fused with the KpnI site of tln-K/pBs.
After complete sequencing, these fusion cDNAs were subcloned into a
pcDNA3 vector.
2.3. Cell culture and transfection
MDCK cells were maintained as described previously [15]. To es-
tablish the MDCK cell lines, stably expressing myc-tagged EP3 iso-
forms, MDCK cells were transfected with their cDNAs by CellPhect
Transfection kit (Pharmacia), and stable transformants were cloned
by selection with G-418 (Gibco BRL). For transient expression,
MDCK cells were transfected with each cDNA by Lipofectamine
2000 reagent (Gibco BRL) for 6 h in Opti-MEM (Gibco BRL), fol-
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lowed by addition of Dulbecco’s modi¢ed Eagle’s medium supple-
mented with 10% fetal bovine serum and incubated for 3 days.
2.4. Immuno£uorescence
MDCK cells were seeded onto poly-L-lysine-coated glass coverslips
in 12-well plates. For localization of EP3 isoforms or tln mutants,
immuno£uorescence microscopy was performed. The cells were ¢xed
in 0.1 M phosphate bu¡er (pH 7.4) containing 4% paraformaldehyde
and 3% sucrose for 30 min at 4‡C. Cells were then permeabilized with
TPBS/HS (10 mM phosphate bu¡er containing 0.1 M NaCl and 0.1%
Tween 20), containing 0.1% Triton X-100 at room temperature for
10 min and washed with TPBS/HS twice. They were blocked with
0.5% bovine serum albumin in TPBS/LS (phosphate-bu¡ered saline
containing 0.05% Tween 20) for 1 h at room temperature and rinsed
with TPBS/HS. To identify the EP3 receptors or tln mutants, cells
were incubated with antibody against myc tag (9E10) (2 Wg/ml) or tln
(1:10 dilution) in TPBS/HS at 4‡C overnight. They were then washed
with TPBS/HS three times and incubated with rhodamine-conjugated
secondary antibody (1:200 dilution) at room temperature for 1 h.
F-actin was visualized with Alexa1488-phalloidin (1:400 dilution),
and used as a marker of the plasma membrane, as described previ-
ously [16]. They were washed with TPBS/HS three times and mounted
onto a slide glass in phosphate-bu¡ered saline/glycerol containing
p-phenylenediamine dihydrochloride. Cells were photographed under
a laser scanning confocal microscope (Bio-Rad, MRC-1024).
3. Results
3.1. Membrane targeting of three EP3 isoforms in MDCK cells
To examine the membrane targeting of the three EP3 iso-
forms, we transiently expressed the myc-tagged isoforms in
MDCK cells. To avoid the e¡ect of endogenously produced
PGE2 on the receptor localization, the cells were pretreated
with indomethacin, a cyclooxygenase inhibitor, before stain-
ing. In the cells expressing EP3K and EP3L isoforms, the
abundant myc staining was present in the intracellular, peri-
nuclear compartment (Fig. 1A,B), while the staining was ob-
served in neither the apical nor the basolateral plasma mem-
brane (Fig. 1E,F). On the other hand, although EP3Q isoform
was in part localized in the intracellular compartment as ob-
served in EP3K- and EP3L-expressing cells, this isoform was
accumulated in the lateral plasma membrane but not in the
apical and basal plasma membranes (Fig. 1C,G). To assess the
role of the C-terminal tails in the membrane targeting, we next
tried to investigate the subcellular localization of T-335, C-
terminal tail-truncation mutant receptor. Similar to EP3K and
L isoforms, transiently expressed myc-tagged T-335 was local-
ized in the intracellular, perinuclear compartment, and no
staining was seen in the plasma membrane (Fig. 1D,H).
To exclude aberrant localization due to transient overex-
pression of the isoforms, we established the MDCK cell lines
stably expressing the myc-tagged mouse EP3K, L, or Q iso-
form. Scatchard analyses of PGE2 binding to the MDCK
cell membranes expressing each isoform showed that these
isoforms displayed high a⁄nities for PGE2 with dissociation
constants of 4.9 nM for EP3K, 8.1 nM for EP3L and 19.6 nM
for EP3Q isoforms (data not shown). These values are com-
parable to those obtained with CHO cells expressing each
isoform [5,6]. EP3K and EP3L isoforms were localized in the
intracellular, perinuclear region, and there was not enrichment
of both isoforms in the plasma membrane (Fig. 2A,B,D,E).
On the other hand, EP3Q isoform was mainly found in the
lateral plasma membrane, though the isoform was in part
localized in the intracellular compartment (Fig. 2C,F). These
results are well consistent with those obtained by the transient
expression system.
These results taken together demonstrate that three EP3
isoforms show di¡erent subcellular targeting in MDCK cells,
indicating that the C-terminal tails play a crucial role for the
determination of subcellular targeting of EP3 receptors.
We next examined the e¡ect of agonist treatment on the
localization of EP3 isoforms. Whereas sulprostone, an EP3
agonist, did not a¡ect the localization of EP3K and EP3L
isoforms (Fig. 3A,B,D,E), EP3Q isoform in the lateral plasma
Fig. 1. Transient expression of three EP3 isoforms and T-335 in MDCK cells. After MDCK cells transiently transfected with EP3K (A, E, I
and M), EP3L (B, F, J and N), EP3Q (C, G, K and O) or T-335 (D, H, L and P) had been treated with 10 WM indomethacin in serum-free me-
dium for 2 h, they were ¢xed and stained with anti-myc antibody (A^H) and Alexa1488-phalloidin (I^P). They were analyzed by confocal mi-
croscopy (A^D and I^L, x-y images; E^H and M^P, x-z images). The white line represents the section of cells through which the z scan was
made. The arrows indicate the lateral membranes. The results shown are representative of three independent experiments that yielded similar re-
sults. The bar represents 10 Wm.
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membrane disappeared by the incubation with sulprostone
(Fig. 3C,F), suggesting that EP3Q isoform in the lateral plas-
ma membrane was internalized.
3.2. The e¡ects of the C-terminal tails of EP3 isoforms on the
subcellular localization of tln
Tln is a cell adhesion molecule which is distributed in tele-
ncephalic neurons [17,18]. In order to examine membrane
targeting activity of the C-terminal tails of EP3 isoforms, we
constructed the cDNAs for the cytoplasmic domain-truncated
mutant tln (henceforth referred to as ‘tln-S’) and tln harboring
the C-terminal tail of EP3K or EP3Q isoform instead of the
cytoplasmic domain of tln (referred to as ‘tln-K’ or ‘tln-Q’)
(Fig. 4). When wild type tln was transiently expressed in
MDCK cells and stained with anti-tln antibody, wild type
tln was localized mainly in the apical plasma membrane and
additionally in the lateral plasma membrane (Fig. 4A,E). No
staining was observed in the intracellular compartment, cyto-
plasm, and the basal plasma membrane. On the other hand,
tln-S lost the apical membrane targeting activity but was re-
Fig. 2. Stable expression of three EP3 isoforms in MDCK cells. After MDCK cells stably expressing EP3K (A, D, G and J), EP3L (B, E, H
and K) or EP3Q (C, F, I and L) had been treated with 10 WM indomethacin in serum-free medium for 2 h, they were ¢xed and stained with
anti-myc antibody (A^F) and Alexa1488-phalloidin (G^L). They were analyzed by confocal microscopy (A^C and G^I, x-y images; D^F and
J^L, x-z images). The white line represents the section of cells through which the z scan was made. The arrows indicate the lateral membranes.
The results shown are representative of three independent experiments that yielded similar results. The bar represents 10 Wm.
Fig. 3. E¡ect of sulprostone on the subcellular localization of the EP3 isoforms. After MDCK cells stably expressing EP3K (A and D), EP3L
(B and E) or EP3Q (C and F) had been treated with 10 WM indomethacin in serum-free medium for 1 h, they were incubated with (D^F) or
without (A^C) 1 WM sulprostone for 1 h. They were then ¢xed and stained with anti-myc antibody. They were analyzed by confocal microsco-
py. The results shown are representative of three independent experiments that yielded similar results. The bar represents 10 Wm.
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tained in the intracellular compartment (Fig. 4B,F), indicating
that the cytoplasmic domain of tln is required for the apical
membrane targeting. Meanwhile tln-K and tln-Q were localized
in the intracellular compartment but not in the plasma mem-
brane (Fig. 4C,D,G,H).
4. Discussion
We have examined membrane targeting activities of three
EP3 isoforms and presented here that EP3K and L isoforms
were retained in the intracellular compartment while EP3Q
isoform was targeted to the lateral plasma membrane in
MDCK cells. EP3K and L isoforms showed high a⁄nity
PGE2 binding, demonstrating that both isoforms appear to
be functional in the intracellular compartment. In agreement
with this ¢nding, the human EP3K isoform was recently re-
ported to be localized in the nuclear envelope and could a¡ect
transcription of genes and intranuclear calcium transients [19].
Recent studies have revealed intracellular compartment distri-
bution of GPCRs, such as thrombin receptor and dopamine
receptor [20,21]. When the C-terminal tail was truncated from
the EP3 receptor, the mutant receptor without the C-terminal
tail was retained in the intracellular compartment, suggesting
that the C-terminal tails of EP3K and L isoforms have no
ability to recruit the receptor to the plasma membranes.
In contrast to EP3K and L isoforms, EP3Q isoform was
targeted to the lateral plasma membrane in MDCK cells.
Considering localization of C-terminal tail-truncated mutant
T-335 to the intracellular compartment, the C-terminal tail of
EP3Q isoform is a determinant for targeting to the lateral
plasma membrane. The domains of membrane targeting of
GPCRs have been extensively studied, and the C-terminal
domain has been shown to play an important role in the
targeting of several GPCRs. Two subtypes of metabotropic
glutamate receptor, mGluR2 and mGluR7, have been re-
ported to be targeted to the somatodendritic and axonal mem-
branes, respectively, in cultured hippocampal neurons, their
targeting speci¢cities being determined by the sequence of
the C-terminal tail [22]. Besides, Wong et al. reported that
two isoforms of monocyte chemoattractant protein-1 receptor
(CCR2A and CCR2B), which were produced by alternative
splicing and di¡ered in the C-terminal sequence, were distrib-
uted at the cytoplasm and in the plasma membrane, respec-
tively, in HEK293 cells [23]. To assess the membrane targeting
Fig. 4. Expression of tln mutants in MDCK cells. Upper panel: Schematic representation of constructed tln mutants. Open boxes represent the
sequence of tln. Transmembrane domain of tln is shown by closed boxes. Shaded box and stripped box indicate the C-terminal tail of EP3K
and EP3Q isoforms, respectively. The numbers shown above and below the boxes indicate the amino acid numbers of tln and EP3 isoforms, re-
spectively. EC, extracellular domain; TM, transmembrane domain; IC, intracellular domain. Lower panel: After MDCK cells transiently trans-
fected with wild type tln (A, E, I and M), tln-S (B, F, J and N), tln-K (C, G, K and O) or tln-Q (D, H, L and P) had been serum-starved for
2 h, they were ¢xed and stained with anti-tln antibody (A^H) and Alexa1488-phalloidin (I^P). They were analyzed by confocal microscopy
(A^D and I^L, x-y images; E^H and M^P, x-z images). The white line represents the section of cells through which the z scan was made. The
results shown are representative of three independent experiments that yielded similar results. The bar represents 10 Wm.
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activity of the C-terminal tail of EP3Q isoform, we constructed
the unrelated apical protein tln harboring the C-terminal tail
of EP3Q isoform instead of the cytoplasmic domain of tln,
which acts as the targeting signal of tln to the apical mem-
brane. However, the C-terminal tail of EP3Q isoform failed to
recruit tln to the plasma membrane, indicating that the C-
terminal tail of EP3Q isoform is not su⁄cient for the plasma
membrane targeting. Limbird and co-workers have shown
multiple determinants, including the third intracellular loop,
for the basolateral membrane localization of K2A-adrenergic
receptor in MDCK cells [24,25]. In the light of these observa-
tions, although the C-terminal tail of EP3Q isoform is an im-
portant determinant for the lateral membrane targeting, an-
other domain(s) of the receptor appears to be needed for the
targeting.
We here showed that three EP3 isoforms di¡ered in mem-
brane targeting in MDCK cells and the C-terminal tails were
crucial determinants for membrane targeting. Thus, alterna-
tive splicing creates three EP3 isoforms with distinct proper-
ties at the level of subcellular targeting. In cells, especially
polarized cells, di¡erent subcellular targeting of EP3 receptor
isoforms would provide distinct cellular functions of the re-
ceptor dependent on targeted sites, even if the isoforms are
coupled to the same signal transduction pathway. This ¢nding
will be of help in understanding the diversity of cellular re-
sponses to PGE2.
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